Stage III or IV Melanoma Clinical Trial
Official title:
A Phase I/II Study of Concurrent Ipilimumab and Dabrafenib in Unresectable Stage III or Stage IV Melanoma
Phase I/II study of ipilimumab concurrent ipilimumab and dabrafenib as first line treatment
in Stage III or IV melanoma.
Assessing safety of Ipilimumab and dabrafenib in combination. Also, assessing disease
control rates.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT01455103 -
Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma
|
Phase 1 |